Literature DB >> 32475164

Early Cardiac Remodeling Promotes Tumor Growth and Metastasis.

Shimrit Avraham1, Soraya Abu-Sharki1, Rona Shofti2, Tali Haas2, Ben Korin3, Roy Kalfon1, Tom Friedman4, Avinoam Shiran5, Walid Saliba6, Yuval Shaked1, Ami Aronheim1.   

Abstract

Background: Recent evidence suggests that cancer and cardiovascular diseases are associated. Chemotherapy drugs are known to result in cardiotoxicity, and studies have shown that heart failure (HF) and stress correlate with poor cancer prognosis. Yet, whether cardiac remodeling in the absence of HF is sufficient to promote cancer is unknown.
Methods: To investigate the effect of early cardiac remodeling on tumor growth and metastasis colonization, we used transverse aortic constriction (TAC), a model for pressure overload-induced cardiac hypertrophy, and followed it by cancer cell implantation.
Results: TAC-operated mice developed larger primary tumors with higher proliferation rate and displayed more metastatic lesions compared with controls. Serum derived from TAC-operated mice potentiated cancer cell proliferation in vitro, suggesting the existence of secreted tumor-promoting factors. Using RNA-seq data, we identified elevated mRNA levels of Periostin in the hearts of TAC-operated mice. Periostin levels were also found high in the serum following TAC. Interestingly, depletion of Periostin from the serum abrogated the proliferation of cancer cells, conversely, the addition of Periostin enhanced cancer cell proliferation in vitro. Collectively, this is the first study to show that early cardiac remodeling nurtures tumor growth and metastasis, and therefore promotes cancer progression. Conclusions: Our study highlights the importance of early diagnosis and treatment of cardiac remodeling as it may attenuate cancer progression and improve cancer outcome.

Entities:  

Keywords:  Periostin; cancer and stroke; transverse aortic constriction

Year:  2020        PMID: 32475164     DOI: 10.1161/CIRCULATIONAHA.120.046471

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

Review 1.  Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer.

Authors:  Anja Karlstaedt; Javid Moslehi; Rudolf A de Boer
Journal:  Nat Rev Cardiol       Date:  2022-04-19       Impact factor: 32.419

2.  The Function, Role and Process of DDX58 in Heart Failure and Human Cancers.

Authors:  Ping Yu; Peng Liang; Shifeng Pang; Wenjian Yuan; Yuxiang Zhao; Qiaojuan Huang
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

3.  Crosstalk Between the Heart and Cancer: Beyond Drug Toxicity.

Authors:  Javid Moslehi; Qing Zhang; Kathryn J Moore
Journal:  Circulation       Date:  2020-08-17       Impact factor: 29.690

Review 4.  Reverse cardio-oncology: Exploring the effects of cardiovascular disease on cancer pathogenesis.

Authors:  Graeme J Koelwyn; Joseph Pierre Aboumsallem; Kathryn J Moore; Rudolf A de Boer
Journal:  J Mol Cell Cardiol       Date:  2021-09-25       Impact factor: 5.000

5.  Deleterious Effects of Hyperactivity of the Renin-Angiotensin System and Hypertension on the Course of Chemotherapy-Induced Heart Failure after Doxorubicin Administration: A Study in Ren-2 Transgenic Rat.

Authors:  Petr Kala; Hana Bartušková; Jan Piťha; Zdenka Vaňourková; Soňa Kikerlová; Šárka Jíchová; Vojtěch Melenovský; Lenka Hošková; Josef Veselka; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Olga Gawrys; Hana Maxová; Luděk Červenka
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

6.  ATF3 expression in cardiomyocytes and myofibroblasts following transverse aortic constriction displays distinct phenotypes.

Authors:  Abu-Sharki Soraya; Haas Tali; Shofti Rona; Friedman Tom; Kalfon Roy; Aronheim Ami
Journal:  Int J Cardiol Heart Vasc       Date:  2020-12-29

7.  Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Authors:  Rudolf A de Boer; Jean-Sébastien Hulot; Carlo Gabriele Tocchetti; Joseph Pierre Aboumsallem; Pietro Ameri; Stefan D Anker; Johann Bauersachs; Edoardo Bertero; Andrew J S Coats; Jelena Čelutkienė; Ovidiu Chioncel; Pierre Dodion; Thomas Eschenhagen; Dimitrios Farmakis; Antoni Bayes-Genis; Dirk Jäger; Ewa A Jankowska; Richard N Kitsis; Suma H Konety; James Larkin; Lorenz Lehmann; Daniel J Lenihan; Christoph Maack; Javid J Moslehi; Oliver J Müller; Patrycja Nowak-Sliwinska; Massimo Francesco Piepoli; Piotr Ponikowski; Radek Pudil; Peter P Rainer; Frank Ruschitzka; Douglas Sawyer; Petar M Seferovic; Thomas Suter; Thomas Thum; Peter van der Meer; Linda W Van Laake; Stephan von Haehling; Stephane Heymans; Alexander R Lyon; Johannes Backs
Journal:  Eur J Heart Fail       Date:  2020-11-12       Impact factor: 15.534

Review 8.  New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management.

Authors:  Alessandra Cuomo; Francesca Paudice; Giovanni D'Angelo; Giovanni Perrotta; Antonio Carannante; Umberto Attanasio; Martina Iengo; Francesco Fiore; Carlo Gabriele Tocchetti; Valentina Mercurio; Flora Pirozzi
Journal:  Curr Heart Fail Rep       Date:  2021-06-28

Review 9.  A new classification of cardio-oncology syndromes.

Authors:  Rudolf A de Boer; Joseph Pierre Aboumsallem; Valentina Bracun; Douglas Leedy; Richard Cheng; Sahishnu Patel; David Rayan; Svetlana Zaharova; Jennifer Rymer; Jennifer M Kwan; Joshua Levenson; Claudio Ronco; Paaladinesh Thavendiranathan; Sherry-Ann Brown
Journal:  Cardiooncology       Date:  2021-06-21

10.  Predicting Survival for Patients with Malignant Pleural Effusion: Development of the CONCH Prognostic Model.

Authors:  Xin Zhang; Feng-Shuang Yi; Huan-Zhong Shi
Journal:  Cancer Manag Res       Date:  2021-06-14       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.